Vertex Q3 2026 Results: Revenue Rises 12% as Crinetics Deal Reshapes Cash, Margins and Guidance
A business read of the Vertex Q3 2026 results: revenue mix, margins, the $10 billion Crinetics deal, cash and a small guidance raise.
Tag: rare disease drug market
Read More